Artificial intelligence continues to transform biomedical sciences, with notable developments including EMBL's €40 million investment to integrate AI across genomics, proteomics, and drug discovery. New tools such as ShortStop leverage machine learning to identify microproteins within the noncoding genome, promising advancements in biomarker discovery and therapeutic targets. Moreover, AI-driven imaging and diagnostics innovations enable earlier, more precise disease detection, enhancing personalized medicine strategies across oncology and beyond.